FTV logo

Fortive

FTV · What the business does, what can go wrong, and how options sellers approach it

What it does

Fortive is an industrial technology company. It makes professional measurement tools and sells software and services that help organizations maintain equipment, keep workers safe, and manage facilities and compliance.

It reports in two segments. Intelligent Operating Solutions is the larger one. It includes Fluke test and measurement tools, connected worker safety products, and facility and asset management software. Advanced Healthcare Solutions focuses on products and services for healthcare settings, such as infection prevention and instrument tracking.

How it makes money

Fortive sells physical instruments and equipment, then adds software subscriptions and services on top. Hardware is often sold through distributors and direct channels to technicians, engineers and safety teams. Software and services tend to be sold on recurring contracts, which can make a portion of revenue more predictable.

Why investors own it

  • Strong brands that professionals rely on for accuracy and reliability.
  • A mix of recurring software revenue and equipment sales.
  • Exposure to long-running needs such as safety, compliance, facility upkeep and healthcare quality.
  • A history of reshaping the portfolio and using acquisitions to add capabilities.

What can go wrong

Industrial customers can cut back on equipment purchases when the economy slows. Acquisitions can fail to deliver expected benefits or add debt. Competition from larger and smaller technology and instrument makers can pressure pricing. Healthcare spending and hospital budgets can shift. Currency swings and supply chain problems can also hurt results.

What to watch

  • Organic revenue growth (excluding acquisitions and currency)
  • Recurring revenue as a share of the total
  • Operating margins by segment
  • Free cash flow and debt levels
  • Order trends and distributor inventory in the instruments business
  • Acquisition and divestiture announcements
  • Management's full-year guidance updates

Options income angle

Options on FTV are generally available across several expirations, but trading is usually lighter than in mega-cap stocks. Bid-ask spreads can be wider, especially on strikes far from the current price or on longer-dated contracts, so limit orders matter.

Implied volatility tends to rise ahead of quarterly earnings and when investors worry about industrial demand or the broader economy. It often eases after results are released.

One caution for sellers of premium: a sharp move on earnings or a guidance change can quickly push the stock past a strike. A covered call may cap the upside, and a cash-secured put may leave you owning shares at a price that looks worse after a drop. Selling premium over an earnings date adds this gap risk.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 25, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Fortive finished spinning off its Precision Technologies business as Ralliant on June 28, 2025, leaving two segments: Intelligent Operating Solutions and Advanced Healthcare Solutions. Sales growth in 2025 came from higher prices while unit volume fell, and operating margin slipped because of separation-related costs. The company returned cash through share repurchases and cut debt using a dividend from Ralliant.

How the business did

  • Sales: Sales were $4,159.1 million in 2025, compared with $4,080.9 million in 2024. Total revenue growth was 1.9%, and core revenue growth (which strips out acquisitions, divestitures and currency) was 1.7%. Pricing added 2.2% and volume declined 0.6%.
  • Profit: Operating profit margin was 17.3%, down from 17.6%. The filing points to incremental stock-based compensation tied to the Separation (-100 basis points) and discrete restructuring charges (-55 basis points). A basis point is one hundredth of a percentage point.
  • Segments: Intelligent Operating Solutions had sales of $2,856.3 million and an operating margin of 25.8%, helped by gas detection and facilities and asset lifecycle software, while professional instrumentation volume was weaker. Advanced Healthcare Solutions had sales of $1,302.8 million and a 10.6% margin. Demand for sterilization equipment and biomedical test products fell because of changes in healthcare policy.
  • Cash and capital return: Operating cash flow from continuing operations was $1,035.7 million. The company repurchased 30 million shares for approximately $1.61 billion and paid dividends of $92.2 million. Net interest expense fell to $120.5 million from $152.8 million.
  • Unusual items: Fortive received the $1,150.0 million Ralliant Dividend and used part of it to redeem euro notes and repay two term loans. The effective tax rate was 11.5%, compared with 4.7% in 2024.

Risks specific to this company

  • Tariffs and trade: About 44% of 2025 sales came from outside the United States. The filing flags uncertainty after the Supreme Court's IEEPA Ruling, including whether tariff refunds will be available and whether similar tariffs could be reimposed.
  • Government funding: Approximately $417 million of 2025 sales went to the U.S. federal government. Those contracts can be terminated or cut at the government's convenience, and management lists reduced U.S. government spending under H.R.1 as an outlook risk.
  • Debt: Long-term debt was approximately $3.2 billion, and the credit agreement includes a debt-to-EBITDA covenant. Of the principal, $1,191.3 million falls due within one year, and the later-due portion includes $650 million of commercial paper.
  • Spin-off liabilities: Fortive could owe indemnities to Ralliant and Vontier under the separation agreements. If the IRS decided a spin-off was taxable, the company and its shareholders could face significant tax bills.
  • Acquired asset values: Goodwill and other intangibles totaled approximately $9.5 billion. The 2025 test found no impairment, with fair value exceeding carrying value by approximately 1.5x to approximately 4.7x across reporting units.
  • Leadership turnover: The CEO, CFO and Chief People Officer roles all changed hands in 2025 and early 2026.

What management is watching

  • Outlook risks: Management names geopolitical events, tariff changes, the IEEPA Ruling, U.S. government spending cuts, OECD Pillar Two tax rules (a global minimum tax) and separation effects.
  • Currency: If exchange rates at December 31, 2025 held through 2026, currency would add approximately 0.8% to 2026 estimated sales. The company generally does not use derivatives to hedge this.
  • Where money goes: Management says it is investing organically and through acquisitions, with R&D of $259.2 million and capital spending of $105.1 million. It relies on the Fortive Business System (its operating toolkit), pricing and cost actions to offset tariffs.
  • Liquidity: A $2.0 billion revolving credit facility expiring October 18, 2027 had no borrowings outstanding. Management expects sufficient liquidity for the foreseeable future.
  • Measures: Management directs investors to core revenue growth, a non-GAAP measure, along with segment operating margin.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended October 2, 2026, filed October 28, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Fortive reported third-quarter sales growth of 7.8% and core revenue growth of 7.2%. Core revenue is sales excluding acquisitions, divestitures and currency swings. Operating profit margin rose to 21.3% from 15.5%, but most of that jump came from items outside day-to-day operations, mainly separation-related stock compensation that hit the prior year and tariff refunds. The healthcare segment was softer than the instruments segment.

How the business did

  • Sales: Quarterly sales were $1,107.5 million versus $1,027.1 million a year earlier. Year-to-date sales were $3,273.7 million versus $3,036.6 million. Core growth was 7.2% in the quarter and 6.4% year to date. Pricing added 2.3% in both periods, and volume added 4.9% and 4.1%.
  • Margin: The 580 basis point increase (a basis point is one hundredth of a percentage point) breaks down as favorable 35 basis points from volume, pricing and productivity, and favorable 545 basis points from other items. Those include +370 basis points from prior-year separation stock compensation and +160 basis points from tariff refunds. A capitalized software impairment took away 55 basis points. Year-to-date margin was 19.5% versus 16.3%.
  • Segments: Intelligent Operating Solutions had sales of $767.1 million versus $698.8 million, core growth of 9.1%, and operating margin of 29.1% versus 25.9%, led by professional instrumentation. Advanced Healthcare Solutions had sales of $340.4 million versus $328.3 million, core growth of 3.1%, and volume growth of only 0.3%. Its operating margin fell to 11.2% from 12.9% on product mix, employee costs and inflation.
  • Cash and capital: Year-to-date operating cash flow from continuing operations was $832.4 million versus $691.5 million. The company repurchased 17.2 million shares for approximately $1.0 billion and paid dividends of $57.3 million. Net interest expense for the quarter was $38.8 million versus $25.4 million, on higher rates, more debt and less cash. In May the company sold new notes for net proceeds of $1.1 billion and used them to repay $900 million of maturing notes.

What management is watching

  • Tariffs: After the Supreme Court's IEEPA Ruling invalidating certain tariffs, the company recognized refunds of $18.0 million for the quarter and $22.5 million year to date, substantially all received in cash. Management calls future refunds uncertain and expects new tariffs under other authorities.
  • Outlook factors: The filing lists assumptions rather than a numeric forecast. They include conflicts in the Middle East and Ukraine, inflation, currency volatility and reduced U.S. government spending.
  • Spending and tools: Management points to growth investments and R&D of $68.2 million in the quarter versus $62.0 million. It also points to core revenue and the Fortive Business System, its productivity toolkit, for pricing, cost and productivity actions.
  • Liquidity: The company held approximately $377 million of cash and had no borrowings under its $2.0 billion Revolving Credit Facility. It filed an automatic shelf registration on July 20, 2026, which lets it sell securities from time to time.

Follow FTV in Kortex

The Kortex app shows FTV's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.